CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer.

@article{Saltz1996CPT11A,
  title={CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer.},
  author={Leonard Saltz and Yasuhiro Shimada and David Khayat},
  journal={European journal of cancer},
  year={1996},
  volume={32A Suppl 3},
  pages={S24-31}
}
CPT-11 (Campto, irinotecan) is a new topoisomerase I inhibitor and one of very few new cytotoxic agents to demonstrate clinical activity in colorectal cancer since the introduction of 5-fluorouracil (5-FU) into clinical practice almost 40 years ago. Because of the unique mechanism of action of CPT-11, its proven activity in colorectal cancer, and its lack of cross-resistance with 5-FU, the combination of CPT-11 with 5-FU is a logical approach to attempt to improve on the results obtained with… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Chemotherapy-induced diarrhoea.

Current opinion in supportive and palliative care • 2009

Management of hepatic metastases from colorectal cancer.

Clinics in colon and rectal surgery • 2005
View 1 Excerpt

Similar Papers

Loading similar papers…